A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events (Q87623397)
Jump to navigation
Jump to search
scientific article published on 19 August 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events |
scientific article published on 19 August 2014 |
Statements
A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events (English)
Joseph Taddeus Beck
A Keith Stewart
Jatin Shah
Kevin R Kelly
Randi Isaacs
Sanela Bilic
Suman Sen
Nikhil C Munshi